Tatva Chintan Pharma Chem's Q2 FY 2025-26 Quarterly Results
- 16 Nov 2025
Result Summary
- Tatva Chintan Pharma Chem Ltd reported a 5.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 48.5%.
- Its expenses for the quarter were up by 1.8% QoQ and 30.6% YoY.
- The net profit increased 49.2% QoQ and decreased 1603.0% YoY.
- The earnings per share (EPS) of Tatva Chintan Pharma Chem Ltd stood at 4.24 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 124.52 | 118.02 | 83.87 | 5.5% | 48.5% |
Total Expenses | 110.86 | 108.91 | 84.88 | 1.8% | 30.6% |
Profit Before Tax | 13.66 | 9.10 | -1.02 | 50.1% | -1439.2% |
Tax | 3.75 | 2.45 | -0.36 | 53.1% | -1141.7% |
Profit After Tax | 9.92 | 6.65 | -0.66 | 49.2% | -1603.0% |
Earnings Per Share | 4.24 | 2.84 | -0.29 | 49.3% | -1562.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Tatva Chintan Pharma Chem Ltd is a prominent player in the specialty chemicals industry, focusing on manufacturing and marketing a variety of high-quality chemical products. The company is known for its diverse portfolio, which includes products like phase transfer catalysts, structure-directing agents, electrolyte salts for supercapacitor batteries, and pharmaceutical and agrochemical intermediates. These products are essential for numerous applications across different industries, such as pharmaceuticals, automotive, agrochemicals, and electronics. Although the specific recent developments about the company are not detailed here, the consistent growth in key financial metrics suggests ongoing strategic initiatives and market engagements.
Revenue
In the second quarter of the fiscal year 2026, Tatva Chintan Pharma Chem Ltd recorded a total income of ₹124.52 crores, showing an increase from ₹118.02 crores in the first quarter of FY26 and ₹83.87 crores in the corresponding quarter of the previous year (Q2FY25). This represents a quarter-over-quarter (QoQ) growth of 5.5% and a significant year-over-year (YoY) increase of 48.5%. This substantial growth in revenue on both a quarterly and annual basis highlights the company's expanding market presence and possibly enhanced sales volumes or pricing strategies.
Profitability
Tatva Chintan Pharma Chem Ltd demonstrated a marked improvement in profitability in Q2FY26. The profit before tax (PBT) stood at ₹13.66 crores, which is a 50.1% increase from ₹9.10 crores in Q1FY26 and a dramatic turnaround from a loss of ₹1.02 crores in Q2FY25. After accounting for taxes, the profit after tax (PAT) was ₹9.92 crores, up from ₹6.65 crores in the prior quarter and a negative ₹0.66 crores in the same quarter last year. The earnings per share (EPS) followed a similar trend, rising from ₹2.84 in Q1FY26 and a negative ₹0.29 in Q2FY25 to ₹4.24 in Q2FY26. These metrics indicate a strong recovery and growth in profitability over the periods considered.
Operating Metrics
The company's total expenses were reported at ₹110.86 crores in Q2FY26, a slight increase from ₹108.91 crores in Q1FY26, and a significant rise from ₹84.88 crores in Q2FY25, reflecting a 1.8% QoQ and a 30.6% YoY increase. Despite the increase in expenses, the rise in total income contributed to a positive profit margin. The tax expense also increased proportionally with profit, amounting to ₹3.75 crores in Q2FY26, up from ₹2.45 crores in Q1FY26 and a negative value in Q2FY25. The company's ability to maintain growth in profit despite rising expenses suggests efficient cost management and operational effectiveness.